Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA for treatment of CNS ischemic disorders

Journal of Neurochemistry

Volumn 113, Issue 2, 2010, Pages 303-312

  Armstead, William M ^a   Ganguly, Kumkum ^b   Kiessling, J W ^a   Riley, John ^a   Chen, Xiao Han ^a   Smith, Douglas H ^a   Stein, Sherman C ^a   Higazi, Abd A R ^a,c   Cines, Douglas B ^a   Bdeir, Khalil ^a   Zaitsev, Sergei ^a,d   Muzykantov, Vladimir R ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cerebral ischemia; Neurovascular unit; Pediatric; Signaling; Stroke; Tissue plasminogen activator

Indexed keywords

27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; ALTEPLASE; DESMOTEPLASE; DISUFENTON SODIUM; DRUG CARRIER; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROSERPIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AGING; BLOOD BRAIN BARRIER; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ERYTHROCYTE; FIBRINOLYTIC THERAPY; HEMODYNAMICS; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; STROKE; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

AGE FACTORS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; ODDS RATIO; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

ANIMALIA;

EID: 77949673546     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06613.x     Document Type: Review

References (87)

1. Abbott N. J., Ronnback L. Hansson E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41 53.
2. Akkawi S., Nassar T., Tarshis M. et al. (2006) LRP and avB3 mediate tPA-activation of smooth muscle cells. AJP 291, H1351 H1359.
3. Amlie-Lefond C. Fullerton H. J. (2009) Thrombolytics for hyperacute stroke in children. Pediatr. Hematol. Oncol. 26, 138 142.
4. Aoki T., Sumii T., Mori T. et al. (2002) Blood brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33, 2711 2717.
5. Armstead W. M. (1999) Role of endothelin-1 in age dependent cerebrovascular hypotensive responses after brain injury. Am. J. Physiol. 274, H1884 H1894.
6. Armstead W. M. (2000) NOC/oFQ contributes to age dependent impairment of NMDA induced cerebrovasodilation after brain injury. Am. J. Physiol. 279, H2188 H2195.
7. Armstead W. M. (2002) Age dependent NMDA contribution to impaired cerebral hemodynamics following brain injury. Dev. Brain Res. 139, 19 28.
8. Armstead W. M., Cines D. B. Higazi A. A. R. (2005a) Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Dev. Brain Res. 156, 139 146.
9. Armstead W. M., Cines D. B. Higazi A. A. R. (2005b) Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 36, 2265 2269.
10. Armstead W. M., Nassar T., Akkawi S. et al. (2006) Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat. Neurosci. 9, 1150 1155.
11. Armstead W. M., Cines D. B., Bdeir K. et al. (2008) uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res. 1231, 121 131.
12. Armstead W. M., Cines D. B., Bdeir K. et al. (2009a) uPA modulates the age dependent effect of brain injury on cerebral hemodyanamics through LRP and ERK MAPK. J. Cereb. Blood Flow Metab. 29, 524 533.
13. Armstead W. M., Ganguly K. Kiessling J. W. (2009b) Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J. Cereb. Blood Flow Metab. 29, 1463 1474.
14. Armstead W. M., Kiessling W., Riley J. et al. (2009c) tPA contributes to impaired NMDA cerebrovasodilation in newborn pig after traumatic brain injury through activation of JNK MAPK. J. Neurotrauma 26, A-74.
15. Armstead W. M., Riley J., Kiessling W. et al. (2009d) Novel PAI-1 derived peptide protects against impairment of hypercapnic and hypotensive cerebrovasodilation after piglet photothrombosis through inhibition of JNK and preservation of p38 MAPK upregulation. J. Neurosurg. Anesthesiol. 21, 409 410.
16. Backsai B. J., Xia M. Q., Strickland D. K., Rebeck G. W. Hyman B. T. (2000) The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc. Natl Acad. Sci. USA 97, 11551 11556.
17. Benedict S. L., Ni O. K., Schloesser P., White K. S. Bale J. F. (2007) Intra-arterial thrombolysisin a 2-year-old with cardioembolic stroke. J. Child Neurol. 22, 225 227.
18. Cremer S., Berliner Y., Warren D. Jones A. E. (2008) Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature. CJEM 10, 575 578.
19. Danielyan K., Ganguly K., Ding B., Atochin D., Zaitsev S., Murciano J. C., Huang P. L., Kasner S. E., Cines D. B. Muzykantov V. R. (2008) Cerebrovascular thromboprophylaxis by erythrocyte coupled tPA. Circulation 118, 1442 1449.
20. Dawson T. M. Dawson V. L. (2006) Taming the clot buster tPA. Nat. Med. 12, 993 994.
21. DeVeber G. Andrew M. (2001) Cerebral sinovenous thrombosis in children. N. Engl. J. Med. 345, 417 423.
22. Dobbing J. (1974) The later growth of the brain and its vulnerability. Pediatrics 53, 2 6.
23. Faraci F. M. Heistad D. D. (1998) Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol. Rev. 78, 53 97.
24. Fernandez-Monreal M., Lopez-Atalaya J. P., Benchenane K. et al. (2004) Arginine 260 of the amino-terminal domain of the NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of the N-methyl-D-aspartate receptor signaling. J. Biol. Chem. 279, 50850 50856.
25. Ferriero D. M. (2004) Neonatal brain injury. New Engl J Med 351, 1985 1995.
26. Fisher M. Bastan B. (2008) Treating acute ischemic stroke. Curr. Opin. Drug Discov. Devel. 11, 626 632.
27. Fujimoto S., Katsuki H., Ohnishi M. et al. (2008) Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats. J. Cereb. Blood Flow Metab. 28, 506 515.
28. Ganguly K., Krasik T., Medinilla S., Bdeir K., Cines D., Muzykantov V. Murciano J. C. (2005) Blood clearance and activity of erythrocyte-coupled fibrinolytics. J. Pharm. Exp. Ther. 312, 1106 1113.
29. Ganguly K., Goel M. S., Krasik T., Bdeir K., Diamond S. L., Cines D. B., Muzykantov V. R. Murciano J. C. (2006) Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J. Pharmacol. Exp. Ther. 312, 1106 1113.
30. Gunther G., Junker R., Strater R. et al. (2000) Symptomatic ischemic stroke in full-term neonates. Stroke 31, 2437 2441.
31. Hacke W., Kaste M., Fieschi C. et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J. Am. Med. Assoc. 274, 1017 1025.
32. Hosomi N., Lucero J., Heo J. H. et al. (2001) Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke 32, 1341 1348.
33. Iadecola C. (2004) Neurovascular regulation in the normal brain and in Alzheimer's Disease. Nat. Rev. Neurosci. 5, 347 360.
34. Janjua N., Nasar A., Lynch J. K. Qureshi A. I. (2007) Thrombolysis for ischemic stroke in children. Data from the nationwide inpatient sample. Stroke 38, 1850 1854.
35. Jiang Q., Zhang R. I., Zhang Z. G. et al. (2000) Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rats at 1 and 4 hours after embolic stroke. J. Cereb. Blood Flow Metab. 20, 1 7.
36. Kidwell C. S., Latour L., Saver J. L., Alger J. R., Starkman S., Duckwiler G., Jahan R. Vinuela F. (2008) Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 25, 338 343.
37. 3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia. Am. J. Physiol. 296, H862 H867.
38. Kiessling J. W., Muzykantov V., Cines D. B. et al. (2009b) tPA contributes to impaired cerebral hemodynamics after piglet photothrombotic injury through JNK and not ERK MAPK. Stroke 40, 110.
39. Kilic E., Hermann D. M. Hossmann K. A. (1999) Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport 10, 107 111.
40. Kim Y. H., Park J. H., Hong S. H. Koh J. Y. (1999) Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science 284, 647 650.
41. Kraus F. T. Acheen V. I. (1999) Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum. Pathol. 30, 759 769.
42. Kuluz J. W., Prado R., He D., Zhao W., Dietrich W. D. Watson B. (2007) New pediatric model of ischemic stroke in infant piglets by photothrombosis. Stroke 38, 1932 1937.
43. Laher I. Zhang J. H. (2001) Protein kinase C and cerebral vasospasm. J. Cereb. Blood Flow Metab. 21, 887 906.
44. Lansberg M. G., Bluhmki E. Thijs V. N. (2009) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke. Stroke 40, 2438 2441.
45. Lapchak P. A. (2002) Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr. Neurol. Neurosci. Rep. 2, 1 6.
46. Lapchak P. A. Araujo D. M. (2001) Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 15, 819 829.
47. Lapchak P. A. Araujo D. M. (2007) Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin. Emerg. Drugs 12, 97 112.
48. Lee S. R., Guo S. Z., Scannevin R. H. et al. (2007) Induction of matrix metalloproteinase, cytokines, and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci. Lett. 417, 1 5.
49. Liu W., Hendren J., Qin X. J. et al. (2009) Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 40, 2526 2531.
50. Lo E. H., Dalkara T. Moskowitz M. A. (2003) Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 4, 399 415.
51. Lo E. H., Broderick J. P. Moskowitz M. A. (2004) tPA and proteolysis in the neurovascular unit. Stroke 35, 354 356.
52. Lynch J. K., Hirtz D. G., DeVeber G. Nelson K. B. (2002) Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics 109, 116 123.
53. Machado L. S., Sazonova I. Y., Kozak A. et al. (2009) Minocycline and tissue-type plasminogen activator for stroke. Assessment of interaction potential. Stroke 40, 3028 3033.
54. Matsuo Y., Mihara S., Ninomiya M. et al. (2001) Protective effect of endothelin typa a receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 32, 2143 2148.
55. Melchor J. P., Pawlak R. Strickland S. (2003) The tissue plasminogen activator-plasminogen proteolytic cascade amyloid β (Aβ) degradation and inhibits Aβ-induced neurodegeneration. J. Neurosci. 23, 8867 8871.
56. Meng W., Wang X., Asahi M. et al. (1999) Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 19, 1316 1321.
57. Meretoja A. Tatlisumak T. (2008) Novel thrombolytic drugs. Will they make a difference in the treatment of ischemic stroke?. CNS Drugs 22, 619 629.
58. Murciano J. C., Medinilla S., Eslin D., Atochina E., Cines D. B. Muzykantov V. R. (2003) Pro-phylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat. Biotechnol. 21, 891 896.
59. Nagai N., Zhao B. Q., Suzuki Y. et al. (2002) Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J. Cereb. Blood Flow Metab. 22, 648 651.
60. Nassar T., Haj-Yehia A., Akkawi S. et al. (2002) Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J. Biol. Chem. 277, 40499 404504.
61. Nassar T., Akkawi S., Shina A. et al. (2004) The in vitro and in vivo effect of tPA and PAI-1 on blood vessel tone. Blood 103, 897 902.
62. Nelson K. B. Lynch J. K. (2004) Stroke in newborn infants. Lancet Neurol. 3, 150 158.
63. Nicole O., Docagne F., Ali C., Margaill I. et al. (2001) The proteolytic activity of tissue plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7, 59 64.
64. Niwa K., Younkin L., Ebeling C. et al. (2000) Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl Acad. Sci. USA 97, 9735 9740.
65. Orth K., Madison E. L., Gething M. J. et al. (1992) Complexes of tissue-type plasminogen activator and its serpin inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Proc. Natl Acad. Sci. USA 89, 7422 7426.
66. Osterwalder T., Contartese J., Stoeckli E. T. et al. (1996) Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J. 15, 2944 2953.
67. Paciaroni M., Medeiros E. Bogousslavsky J. (2009) Desmoteplase. Expert Opin. Biol. Ther. 9, 773 778.
68. Parathath S. R., Parathath S. Tsirka S. E. (2006) Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice. J. Cell Sci. 119, 339 349.
69. Park L., Gallo E. F., Anrather J. et al. (2008) Key role of tissue plasminogen activator in neuro-vascular coupling. Proc. Natl Acad. Sci. USA 105, 1073 1078.
70. Pawlak R., Melchor J. P., Matys T. et al. (2005) Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc. Natl Acad. Sci. USA 102, 443 448.
71. Perkins E., Stephens J., Xiang H. Lo W. (2009) The cost of pediatric stroke acute care in the United States. Stroke 40, 2820 2827.
72. Polavarapu R., Gongora M. C., Ranganthan S., Lawrence D. A., Strickland D. Yepes M. (2007) Tissue-type plasminogen activator-mediated shedding of astrocytic low density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood 109, 3270 3278.
73. Shaver E. G., Duhaime A. C., Curtis M., Gennarelli L. M. Barrett R. (1996) Experimental acute subdural hematoma in infant piglets. Pediatr. Neurosurg. 125, 123 129.
74. Shuaib A., Lees K. R., Lyden P. et al. (2007) NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 357, 562 571.
75. Stein S. C., Ganguly K., Belfeld C. M. et al. (2009) Erythrocyte bound tissue plasminogen activator (tPA) is neuroprotective in experimental traumatic brain injury. J. Neurotrauma 26, 1585 1592.
76. Su E. J., Fredriksson L., Geyer M. et al. (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood brain barrier integrity during ischemic stroke. Nat. Med. 14, 731 737.
77. Tabrizi P., Wang L., Seeds N. et al. (1999) Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA deficient mice and wild-type mice on a matched genetic background. Arterioscler. Thromb. Vasc. Biol. 19, 2801 2806.
78. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581 1587.
79. Tsirka S. E., Gualandris A., Amaral D. G. et al. (1995) Excitotoxin-induced neuronal degenera-tion and seizure are mediated by tissue plasminogen activator. Nature 377, 340 344.
80. Tsuji K., Aoki T., Tejima E. et al. (2005) Tissue plasminogen activator promotes matrix metallo-proteinase-9 upregulation afer focal cerebral ischemia. Stroke 36, 1954 1959.
81. Van Mourik J. A., Lawrence D. A. Loskutoff D. J. (1984) Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem. 259, 14914 14921.
82. Wang Y. F., Tsirka S. E., Strickland S. et al. (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild type and tPA-deficient mice. Nat. Med. 4, 228 231.
83. Yepes M., Sandkvist M., Moore E. G. et al. (2003) Tissue-type plasminogen activator induces opening of the blood brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 1533 1540.
84. Yepes M., Roussel B. D., Ali C. et al. (2009) Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 32, 48 55.
85. Zaitsev S., Danielyan K., Murciano J. C., Krasik T., Taylor R. P., Pincus S., Jones S. M., Cines D. B. Muzykantov V. R. (2006) CR-1-directed targeting of tPA to circulating erythrocytes for prophylactic fibrinolysis. Blood 108, 1895 1902.
86. Zhang R. L., Zhang C., Zhang L. et al. (2008) Synergistic effect of an endothelin type A receptor antagonist, S-0139, with tPA on the neuroprotection after embolic stroke. Stroke 39, 2830 2836.
87. del Zoppo G. J. Mabuchi T. (2003) Cerebral microvessel responses to focal ischemia. J. Cereb. Blood Flow Metab. 23, 879 894.